Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$0.40
-2.4%
$1.46
$0.38
▼
$25.56
$990K1.6592,181 shs148,734 shs
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$2.66
$2.05
$1.75
▼
$3.07
$19.78M0.2499,210 shs148,459 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-2.37%-31.98%-74.74%-84.92%-98.16%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.00%+49.44%+35.71%+12.24%+33.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$0.40
-2.4%
$1.46
$0.38
▼
$25.56
$990K1.6592,181 shs148,734 shs
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$2.66
$2.05
$1.75
▼
$3.07
$19.78M0.2499,210 shs148,459 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-2.37%-31.98%-74.74%-84.92%-98.16%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.00%+49.44%+35.71%+12.24%+33.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
1.00
SellN/AN/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
2.00
Hold$8.60223.31% Upside

Current Analyst Ratings Breakdown

Latest AYTU and APVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
UpgradeSell (E) ➝ Sell (E+)
11/17/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
DowngradeBuy ➝ Hold
11/17/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
DowngradeBuy ➝ Hold$2.70
10/29/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
DowngradeSell (E+) ➝ Sell (E)
10/14/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
UpgradeSell (E) ➝ Sell (E+)
10/6/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
DowngradeSell (D) ➝ Sell (D-)
10/5/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
DowngradeHold ➝ Strong Sell
9/25/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
DowngradeSell (E+) ➝ Sell (E)
9/22/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Reiterated RatingPositive
9/22/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
UpgradeSell (D-) ➝ Sell (D)
9/10/2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
UpgradeSell (E) ➝ Sell (E+)
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/A$17.42 per shareN/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$57.57M0.50N/AN/A$3.29 per share0.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$25.97M-$51.83N/AN/AN/AN/A-217.57%-123.71%N/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$14.25M-$1.78N/A19.00N/A-34.34%-74.74%-18.67%2/2/2027 (Estimated)

Latest AYTU and APVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$3.71-$5.19-$1.48-$5.19N/AN/A
11/16/2026Q1 2027
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$0.2567-$0.20+$0.0567-$0.20$13.27 million$14.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
2.08
2.08
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.26
1.13
1.00

Institutional Ownership

CompanyInstitutional Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
8.06%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
33.49%

Insider Ownership

CompanyInsider Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.37%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
6.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
331.81 million3.45 millionNot Optionable
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
7610.87 million10.20 millionNot Optionable

Recent News About These Companies

Aytu BioPharma (NASDAQ:AYTU) Stock Rating Lowered by Maxim Group
Aytu BioPharma (NASDAQ:AYTU) Stock Rating Lowered by Lake Street Capital
Rosemont Pharmaceuticals to Buy Aytu BioPharma

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$0.40 -0.01 (-2.37%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.41 +0.00 (+1.21%)
As of 11/20/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Aytu BioPharma stock logo

Aytu BioPharma NASDAQ:AYTU

$2.66 0.00 (0.00%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.66 -0.01 (-0.19%)
As of 11/20/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.